氯胺酮与吗啡用于院前创伤疼痛镇痛:一项随机临床试验
KETAMORPH研究为多中心、单盲、非劣效随机临床试验,纳入法国11个院前急救单位中口头疼痛评分≥5分的成人创伤患者,比较静脉氯胺酮(20 mg,随后每5分钟10 mg)与吗啡(每5分钟2或3 mg)。共251例随机(氯胺酮128例、吗啡123例),主要终点为给药前至30分钟后口头疼痛评分平均变化组间差,非劣效界值1.3。氯胺酮组疼痛评分变化-3.7(95%CI -4.2至-3.2),吗啡组-3.8(95%CI -4.2至-3.4),组间差0.1分(95%CI -0.7至0.9),达到非劣效。氯胺酮组不良反应更多(40.8% vs 16.8%),最常见为涌现现象(20.0%),吗啡组最常见为恶心(10.6%),无不良事件需干预。
要点
- 院前创伤疼痛成人(口头疼痛评分≥5分)静脉氯胺酮20 mg后每5分钟10 mg,较吗啡每5分钟2或3 mg,30分钟疼痛评分变化组间差0.1分(95%CI -0.7至0.9),非劣效界值1.3,达到非劣效。
- 氯胺酮组疼痛评分平均变化-3.7(95%CI -4.2至-3.2),吗啡组-3.8(95%CI -4.2至-3.4)。
- 氯胺酮组不良反应49/120(40.8%,95%CI 32.0%-49.6%),最常见涌现现象24/120(20.0%);吗啡组19/113(16.8%,95%CI 10.4%-25.0%),最常见恶心12/113(10.6%)。
- 两组生命体征无临床意义差异,无不良事件需干预。
- 作者认为在阿片危机背景下,氯胺酮单药是院前创伤疼痛成人的阿片类替代选择。
适用人群与场景
- 成人院前创伤患者,口头疼痛评分≥5分,纳入法国11个院前急救单位,2017年11月23日至2022年11月26日入组。
诊断标准与关键阈值
- 口头疼痛评分≥5分。
- 非劣效界值为1.3分。
处置流程与药物剂量
- 氯胺酮组:静脉氯胺酮20 mg,随后每5分钟10 mg。
- 吗啡组:静脉吗啡每5分钟2或3 mg。
研究设计与关键结果
- 多中心、单盲、非劣效随机临床试验(KETAMORPH),251例随机(氯胺酮128例、吗啡123例),中位年龄51岁(IQR 34-69),247例有数据者中女性111例(44.9%)、男性140例(55.1%),意向治疗分析。
- 主要终点:给药前至30分钟口头疼痛评分平均变化,氯胺酮组-3.7(95%CI -4.2至-3.2) vs 吗啡组-3.8(95%CI -4.2至-3.4),组间差0.1分(95%CI -0.7至0.9),达到非劣效。
- 两组生命体征无临床意义差异。
- 不良反应:吗啡组19/113(16.8%,95%CI 10.4%-25.0%),最常见恶心12/113(10.6%);氯胺酮组49/120(40.8%,95%CI 32.0%-49.6%),最常见涌现现象24/120(20.0%)。
- 无不良事件需干预。
证据类型、等级与局限
- 证据类型:多中心、单盲、非劣效随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在持续的阿片危机背景下,氯胺酮单药是院前创伤疼痛成人的阿片类替代选择。
指南或共识出处
- KETAMORPH研究,注册号ClinicalTrials.gov NCT03236805。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Pain is a common out-of-hospital symptom among patients, and opioids are often prescribed. Research suggests that overprescribing for acute traumatic pain is still prevalent, even when limits restricting opioid prescriptions have been implemented. Ketamine hydrochloride is an alternative to opioids in adults with out-of-hospital traumatic pain.
OBJECTIVE: To assess the noninferiority of intravenous ketamine compared with intravenous morphine sulfate to provide pain relief in adults with out-of-hospital traumatic pain.
DESIGN, SETTING, AND PARTICIPANTS: The Intravenous Subdissociative-Dose Ketamine Versus Morphine for Prehospital Analgesia (KETAMORPH) study was a multicenter, single-blind, noninferiority randomized clinical trial comparing ketamine hydrochloride (20 mg, followed by 10 mg every 5 minutes) with morphine sulfate (2 or 3 mg every 5 minutes) in adult patients with out-of-hospital trauma and a verbal pain score equal to or greater than 5. Enrollment occurred from November 23, 2017, to November 26, 2022, in 11 French out-of-hospital emergency medical units.
INTERVENTIONS: Patients were randomly assigned to ketamine (n = 128) or morphine (n = 123).
MAIN OUTCOMES AND MEASURES: The primary outcome was the between-group difference in mean change in verbal rating scale pain scores measured from the time before administration of the study drug to 30 minutes later. A noninferiority margin of 1.3 was chosen.
RESULTS: A total of 251 patients were randomized (median age, 51 [IQR, 34-69] years; 111 women [44.9%] and 140 men [55.1%] among the 247 with data available) and were included in the intention-to-treat population. The mean pain score change was -3.7 (95% CI, -4.2 to -3.2) in the ketamine group compared with -3.8 (95% CI, -4.2 to -3.4) in the morphine group. The difference in mean pain score change was 0.1 (95% CI, -0.7 to 0.9) points. There were no clinically meaningful differences for vital signs between the 2 groups. The intravenous morphine group had 19 of 113 (16.8% [95% CI, 10.4%-25.0%]) adverse effects reported (most commonly nausea [12 of 113 (10.6%)]) compared with 49 of 120 (40.8% [95% CI, 32.0%-49.6%]) in the ketamine group (most commonly emergence phenomenon [24 of 120 (20.0%)]). No adverse events required intervention.
CONCLUSIONS AND RELEVANCE: In the KETAMORPH study of patients with out-of-hospital traumatic pain, the use of intravenous ketamine compared with morphine showed noninferiority for pain reduction. In the ongoing opioid crisis, ketamine administered alone is an alternative to opioids in adults with out-of-hospital traumatic pain.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03236805.
参考来源
- Le Cornec C, Le Pottier M, Broch H, et al. Ketamine Compared With Morphine for Out-of-Hospital Analgesia for Patients With Traumatic Pain: A Randomized Clinical Trial. JAMA Netw Open. 2024. PMID: 38285446. doi:10.1001/jamanetworkopen.2023.52844
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。